Comprehensive Clinical Monograph: Perampanel (Fycompa®)

Part I: Introduction and Drug Profile

1.1 Overview and Therapeutic Class

Perampanel is a first-in-class antiepileptic drug (AED) that represents a novel therapeutic approach to the management of epilepsy.[1] Marketed by Eisai Co. under the brand name Fycompa®, it is distinguished by its unique mechanism of action as a selective, non-competitive antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor.[3] This positions it as a targeted therapy against the principal excitatory neurotransmitter pathway implicated in seizure generation and propagation.

Perampanel is primarily indicated for the treatment of epilepsy. Its initial approvals were for adjunctive therapy in patients with partial-onset seizures (POS), with or without secondary generalization, and for primary generalized tonic-clonic (PGTC) seizures.[4] Subsequently, its label has expanded to include monotherapy for POS in certain patient populations, broadening its clinical utility.[6]

1.2 Chemical and Physical Properties

From a chemical standpoint, perampanel is a complex small molecule belonging to the bipyridine class of compounds. Its structure is specifically defined as a 2,3'-bipyridin-6'-one substituted at the 1'-position with a phenyl group and at the 5'-position with a 2-cyanophenyl group. This unique configuration also classifies it as a pyridone and a nitrile.[5]

The molecular formula for perampanel is C23​H15​N3​O, and it has a molecular weight of 349.4 g/mol.[7] In its purified form, it exists as a crystalline solid. Its solubility characteristics show it is soluble in acetonitrile at concentrations greater than 1 mg/ml, while being only slightly soluble in common laboratory solvents like chloroform and dimethyl sulfoxide (DMSO).[8]

Table 1: Perampanel Drug Identifiers

Identifier Type	Value	Source(s)
Generic Name	Perampanel	9
Brand Name	Fycompa®	3
DrugBank ID	DB08883	5
CAS Number	380917-97-5	5
UNII	H821664NPK	5
ChEBI ID	CHEBI:71013	5
ChEMBL ID	CHEMBL1214124	5
KEGG ID	D08964	5
PubChem CID	9925695	5

1.3 Formulations and Presentation

Perampanel is formulated for oral administration and is available in two distinct forms to accommodate different patient needs: film-coated tablets and an oral suspension.[5] This dual formulation approach enhances its applicability, particularly for pediatric patients and individuals who may have difficulty swallowing solid dosage forms.

The tablets are available in a wide range of strengths: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. To ensure patient safety and prevent medication errors, each tablet strength is uniquely colored and debossed with its corresponding dose number.[10]

The oral suspension is a white to off-white opaque liquid provided at a concentration of 0.5 mg/mL. It is intended for precise dosing using a supplied adapter and graduated oral syringe.[10]

Part II: Regulatory and Developmental History

2.1 Discovery and Development

Perampanel, initially coded as E2007, was discovered and developed through the in-house research programs of Eisai Co., a Japan-based pharmaceutical company.[1] The initial scope of its clinical development was broad, with investigations into its potential for treating several neurological conditions, including Parkinson's disease, neuropathic pain, and multiple sclerosis.[3]

However, in a key strategic decision announced in April 2008, Eisai terminated the development programs for these other indications to concentrate its resources exclusively on the epilepsy program.[4] This pivot suggests that early clinical data likely revealed that the drug's most promising therapeutic window—the balance between efficacy and tolerability—was within the context of epilepsy. While its potent glutamatergic antagonism was theoretically applicable to other CNS disorders, the risk-benefit profile was ultimately deemed most favorable for treating seizures, solidifying its identity as a specialized antiepileptic agent.

2.2 Global Regulatory Approvals

Perampanel's path to market involved submissions to major global regulatory bodies, with key approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) establishing its role in modern epilepsy treatment.

The first major marketing authorization came from the European Commission on July 27, 2012, which approved Fycompa for the adjunctive treatment of partial-onset seizures in patients aged 12 years and older.[2] This landmark approval was based on a robust data package from three pivotal Phase III clinical trials (Studies 304, 305, and 306), which collectively enrolled 1,480 patients with refractory epilepsy.[2]

In the United States, the regulatory journey involved a resubmission of its New Drug Application (NDA 202834) in late 2011 after an initial response from the FDA.[9] The FDA granted its first approval on October 22, 2012, for the same initial indication as in Europe: adjunctive treatment of POS in patients aged 12 and older.[9] This was followed by a series of label expansions that significantly broadened its approved uses, as detailed in Table 2.

Table 2: Key Regulatory Approval Milestones (FDA & EMA)

Date	Regulatory Body	Action/Indication	Significance
July 27, 2012	EMA	Approved for adjunctive treatment of POS (≥12 years)	First global approval for perampanel, establishing a new class of AED 2
Oct 22, 2012	FDA	Approved for adjunctive treatment of POS (≥12 years)	U.S. market entry for a novel mechanism in epilepsy treatment 6
June 22, 2015	FDA	Approved for adjunctive treatment of PGTC seizures (≥12 years)	Expanded indication to a form of generalized epilepsy based on a single pivotal trial 6
May 2, 2016	FDA	Oral suspension formulation approved	Provided a liquid alternative, improving access for pediatric and dysphagic patients 6
July 27, 2017	FDA	Approved as monotherapy for POS (≥12 years)	First approval as a standalone therapy, based on PK extrapolation of efficacy 6
Sep 28, 2018	FDA	Approved for POS in pediatric patients (≥4 years)	Extended use to younger children, also based on PK extrapolation 6

The FDA's approval of perampanel for monotherapy and pediatric use based on pharmacokinetic (PK) extrapolation is a noteworthy regulatory development.[6] Rather than requiring new, large-scale, placebo-controlled trials for these settings, the agency accepted that if similar drug exposure levels (as measured by area under the curve, or AUC) could be achieved in these new populations, a similar efficacy outcome could be expected. This pragmatic approach relies on the scientific conclusion that partial-onset seizures are fundamentally similar in adults and children down to age 4, and that the drug's exposure-response relationship is well-understood.[6] While this provides a more efficient path to label expansion, it is important for clinicians to recognize that the direct evidence base for these indications is derived differently than that for the original adjunctive approval.

2.3 Controlled Substance Scheduling

In the United States, perampanel's regulatory profile includes its classification as a Schedule III controlled substance by the Drug Enforcement Administration (DEA).[1] This designation, which is uncommon among AEDs, reflects a recognized potential for abuse and psychological dependence. This scheduling decision was informed by clinical studies in which supratherapeutic doses of perampanel produced subjective effects of euphoria and dissociative phenomena that were compared to ketamine, a known drug of abuse.[3]

This classification has significant practical implications, imposing stricter requirements for prescribing, dispensing, and inventory management. Furthermore, the link to ketamine-like effects provides a crucial connection between the drug's pharmacology and its adverse event profile. Ketamine is a well-known antagonist of the NMDA receptor, another critical glutamate receptor in the brain. The fact that perampanel, an AMPA receptor antagonist, can produce similar psychoactive effects underscores that its abuse potential is not an arbitrary side effect but is intrinsically linked to its powerful modulation of the brain's primary excitatory neurotransmitter system. This same mechanism that controls seizures also governs perception, mood, and behavior, directly connecting its therapeutic action to its abuse liability and its risk for serious psychiatric side effects.

Part III: Pharmacology and Mechanism of Action

3.1 A Novel Mechanism: AMPA Receptor Antagonism

Perampanel introduced a new paradigm in epilepsy treatment as the first and, to date, only approved AED that functions as a selective, non-competitive antagonist of the AMPA glutamate receptor.[5] This mechanism of action is fundamentally different from those of established AEDs, which typically exert their effects by modulating voltage-gated ion channels (e.g., sodium, calcium) or by enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).[2] By targeting the glutamatergic system directly, perampanel offers a distinct therapeutic strategy for seizure control.

3.2 Role of Glutamate and AMPA Receptors in Seizure Pathophysiology

The pathophysiology of epilepsy is fundamentally rooted in a state of neuronal hyperexcitability, leading to the hypersynchronous firing of neuronal populations that manifests as a seizure.[15] Glutamate is the most abundant and principal excitatory neurotransmitter in the central nervous system, playing a critical role in mediating fast synaptic transmission.[11]

AMPA receptors are a key subtype of ionotropic glutamate receptors located on postsynaptic neurons. They are essential for mediating this rapid excitatory signaling. When glutamate is released into the synapse and binds to AMPA receptors, it triggers the opening of their associated ion channels, allowing a rapid influx of sodium ions (Na+) into the neuron. This influx causes depolarization of the postsynaptic membrane, increasing the likelihood that the neuron will fire an action potential.[14] In the context of epilepsy, this glutamatergic pathway is believed to be overactive, contributing directly to both the initiation of a seizure focus and the subsequent propagation or spread of seizure activity throughout the brain.[4]

3.3 Molecular Action of Perampanel

Perampanel exerts its therapeutic effect through a precise molecular interaction with the AMPA receptor. It functions as a negative allosteric modulator, meaning it binds to a site on the receptor that is physically distinct from the binding site for glutamate.[3] This allosteric binding induces a conformational change in the receptor protein, which in turn reduces the receptor's ability to respond to glutamate.

Electrophysiological studies have demonstrated that this interaction results in a slow, concentration-dependent inhibition of AMPA receptor-mediated currents, effectively dampening the excitatory signal. Importantly, this effect is highly selective for AMPA receptors, with no significant impact on the function of NMDA receptors, another major type of glutamate receptor.[3] By reducing the excitatory drive mediated by glutamate, perampanel effectively raises the seizure threshold and limits the spread of epileptic activity, thereby exerting its potent anticonvulsant effect.[11]

The non-competitive nature of this antagonism is a key pharmacological advantage. During an active seizure, the concentration of glutamate in the synaptic cleft can rise to extremely high levels. A competitive antagonist, which vies with glutamate for the same binding site, could potentially be overwhelmed and displaced by this surge, diminishing its efficacy. In contrast, perampanel's inhibitory effect is independent of the glutamate concentration because it acts at a different site. This ensures that its blocking action remains robust even in the face of the massive glutamate release that characterizes intense seizure activity. This resilient mechanism may be a contributing factor to its demonstrated efficacy in patients with treatment-refractory epilepsy who have not responded to other AEDs.

Part IV: Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination (ADME)

4.1 Absorption

Perampanel exhibits favorable absorption characteristics following oral administration. It is absorbed rapidly and completely, with a high absolute bioavailability of approximately 100%, indicating that there is negligible first-pass metabolism in the liver.[5] Under fasted conditions, the median time to reach peak plasma concentration (Tmax) is relatively short, ranging from 0.5 to 2.5 hours.[15]

The presence of food influences the rate but not the extent of absorption. When taken with a high-fat meal, the overall exposure to the drug, as measured by the area under the concentration-time curve (AUC), is not affected. However, the rate of absorption is slowed, resulting in a reduction in the peak plasma concentration (Cmax) by up to 40% and a delay in Tmax by approximately 2 to 3 hours.[15] This lack of a significant food effect on total exposure provides flexibility in administration, allowing patients to take the medication with or without food.[11] The blunting of the peak concentration when taken with food may also be clinically advantageous, as it could potentially mitigate peak-dose-related side effects such as dizziness or somnolence.

4.2 Distribution

Once in the systemic circulation, perampanel is extensively bound to plasma proteins, with a binding fraction of approximately 95% to 96%.[15] It primarily binds to two key proteins: albumin and α1-acid glycoprotein (AAG).[16] Despite its extensive distribution into tissues, the apparent volume of distribution (

Vd​) has not been formally quantified in human studies.[5]

4.3 Metabolism

Perampanel undergoes extensive metabolism, primarily in the liver, before elimination. The main metabolic pathway involves primary oxidation, which is then followed by sequential glucuronidation to form more water-soluble conjugates.[15]

In vitro studies using human liver microsomes have definitively identified the Cytochrome P450 3A4 and/or 3A5 (CYP3A4/5) isoenzymes as being principally responsible for the oxidative metabolism of perampanel.[15] This heavy reliance on the CYP3A4 pathway is the most critical pharmacokinetic feature of the drug, as it is the primary driver of clinically significant drug-drug interactions. A vast number of medications, including several commonly prescribed AEDs, are known to either induce or inhibit the activity of CYP3A4. Co-administration of perampanel with these agents can therefore lead to substantial alterations in its plasma concentrations, necessitating dose adjustments to maintain efficacy and safety. This direct link between a specific metabolic pathway and clinical practice is reflected in the FDA's dosing guidelines, which mandate a higher starting dose for patients taking potent CYP3A4-inducing drugs.[10]

4.4 Elimination

Perampanel is characterized by a very long elimination half-life (t1/2​), which is approximately 105 hours in individuals not taking concomitant enzyme-inducing medications.[15] This long half-life is clinically advantageous as it supports a convenient once-daily dosing regimen and contributes to relatively stable plasma concentrations between doses. It also means that steady-state plasma concentrations are not achieved for two to three weeks after initiation or a dose change.[4]

The half-life is dramatically shortened in the presence of strong CYP3A inducers. For example, when co-administered with carbamazepine, the average half-life of perampanel is reduced to approximately 25 hours.[17]

The drug is eliminated from the body almost exclusively as metabolites. Following administration of a radiolabeled dose, approximately 70% of the radioactivity is recovered in the feces, with the remaining 30% recovered in the urine.[17] The apparent clearance of perampanel in healthy male subjects is approximately 12 mL/min (0.73 L/h).[5]

Table 3: Summary of Key Pharmacokinetic Parameters of Perampanel

Parameter	Value (without inducers)	Value (with strong CYP3A inducers)	Clinical Implication
Bioavailability	~100%	~100%	Complete absorption, predictable oral dosing 15
Tmax (fasted)	0.5 - 2.5 hours	0.5 - 2.5 hours	Rapid absorption after oral dose 15
Protein Binding	95-96%	95-96%	High binding, primarily to albumin and AAG 15
Primary Metabolic Pathway	CYP3A4/5 oxidation	CYP3A4/5 oxidation	High potential for drug-drug interactions 15
Elimination Half-life (t1/2​)	~105 hours	~25 hours	Supports once-daily dosing; requires dose adjustment with inducers 15
Time to Steady State	2-3 weeks	~5 days	Dose changes require time to reflect in plasma levels 4
Route of Elimination	Feces (~70%), Urine (~30%)	Feces (~70%), Urine (~30%)	Primarily eliminated as metabolites, not parent drug 17

Part V: Clinical Efficacy and Pivotal Trials

5.1 Approved Indications

Perampanel has secured regulatory approval for specific types of seizures in defined patient populations, reflecting the evidence generated from its clinical development program.

• Partial-Onset Seizures (POS): Perampanel is indicated for the treatment of POS, with or without secondary generalization. In the United States and Europe, it is approved as both adjunctive therapy and monotherapy for patients with epilepsy aged 4 years and older.[6]
• Primary Generalized Tonic-Clonic (PGTC) Seizures: It is also indicated as an adjunctive therapy for the treatment of PGTC seizures in patients with idiopathic generalized epilepsy. The approved age range is 12 years and older in the U.S. and 7 years and older in the E.U..[5]

5.2 Adjunctive Therapy for Partial-Onset Seizures: Pivotal Phase III Trials

The foundational evidence supporting perampanel's efficacy in POS comes from a trio of large, global, randomized, double-blind, placebo-controlled Phase III trials: Study 306, Study 304, and Study 305.[1] These studies were conducted in patients aged 12 years and older with refractory POS, meaning their seizures were not adequately controlled despite treatment with one to three other AEDs.[13] The trial design consistently involved a baseline observation period, a 6-week dose-titration phase, and a 13-week maintenance phase at the target dose.[13]

To satisfy the requirements of different global regulatory agencies, the trials utilized two distinct primary endpoints: the 50% responder rate (the proportion of patients achieving a 50% or greater reduction in seizure frequency), which was the primary endpoint for the EMA; and the median percent change in seizure frequency from baseline, which was the primary endpoint for the FDA.[1]

Table 4: Summary of Pivotal Phase III Trials for Partial-Onset Seizures (Studies 304, 305, 306)

Study ID	Doses Studied (mg/day)	N (Perampanel/Placebo)	Median % Seizure Reduction (vs. Placebo)	50% Responder Rate (vs. Placebo)	Key Finding
306	2, 4, 8	531 / 175	4mg: -23.3% vs -10.7% (p=0.0026) 8mg: -30.8% vs -10.7% (p<0.0001)	4mg: 28.5% vs 17.9% (p=0.0132) 8mg: 34.9% vs 17.9% (p=0.0003)	Doses of 4mg and 8mg were effective; 2mg was not superior to placebo 1
304	8, 12	258 / 130	8mg: -26.3% vs -21.0% (p=0.0261) 12mg: -34.5% vs -21.0% (p=0.0158)	8mg: 37.6% vs 26.4% (p=0.0760) 12mg: 36.1% vs 26.4% (p=0.0914)	Both 8mg and 12mg doses showed significant seizure reduction over placebo 1
305	8, 12	258 / 128	8mg: -30.5% vs -9.7% (p=0.0008) 12mg: -17.6% vs -9.7% (p=0.0105)	8mg: 33.3% vs 14.7% (p=0.0018) 12mg: 33.9% vs 14.7% (p=0.0006)	Both 8mg and 12mg doses were significantly more effective than placebo 1

The consistent results across these three large trials, demonstrating superiority over placebo on both primary endpoints, provided a robust evidence base for perampanel's initial approval. A clear dose-response relationship was evident, with higher doses generally conferring greater efficacy.[13] However, it is important to note that these pivotal trials were all placebo-controlled. The absence of an active comparator arm (i.e., comparing perampanel directly to another established AED) makes it difficult to ascertain the "added benefit" of perampanel relative to the existing standard of care from this evidence alone.[3] This positions perampanel as a well-validated option for patients with refractory epilepsy who have failed other therapies, but its precise role as a first- or second-line agent is less clearly defined by these initial studies.

5.3 Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures

The approval for PGTC seizures was based on the results of a single, pivotal Phase III, placebo-controlled trial involving 164 patients with idiopathic generalized epilepsy experiencing PGTC seizures.[6] The study demonstrated a clinically and statistically significant benefit for perampanel. The median percent reduction in PGTC seizure frequency was dramatically greater in the perampanel group (-76.5%) compared to the placebo group (-38.4%), a highly significant difference (

P<0.0001).[15] The 50% responder rate was also significantly higher with perampanel (58%) than with placebo (36%).[11]

5.4 Monotherapy and Pediatric Use

The expansion of perampanel's label to include monotherapy for POS was granted by the FDA based on an extrapolation of efficacy from the adjunctive therapy trials.[6] The regulatory rationale was that if the drug dosages used in a monotherapy setting result in plasma exposures that are similar to those demonstrated to be safe and effective in the adjunctive setting, then similar efficacy can be inferred.[6]

A similar logic was applied to the approval for pediatric use in POS for children aged 4 to 11. This approval was supported by pharmacokinetic modeling designed to identify a pediatric dosing regimen that would produce drug exposures comparable to those seen in the adult population, combined with the regulatory determination that the pathophysiology of POS is sufficiently similar across these age groups to allow for such extrapolation.[6]

Part VI: Safety Profile and Tolerability

6.1 Black Box Warning: Serious Psychiatric and Behavioral Reactions

The most significant safety concern associated with perampanel is highlighted by a black box warning on its FDA label, the agency's most stringent warning. This warning alerts prescribers and patients to the risk of serious or life-threatening psychiatric and behavioral adverse reactions.[5]

• Reported Reactions: The spectrum of reported reactions is broad and severe, including aggression, hostility, irritability, anger, and, most alarmingly, homicidal ideation and threats.[21]
• Patient Population at Risk: A particularly concerning aspect of this risk is that these events have been observed in patients both with and without a prior history of psychiatric illness or aggressive behavior.[3] This implies that all patients starting perampanel should be considered at risk.
• Clinical Management: The FDA mandates close monitoring for these reactions, especially during the initial dose titration period and at higher doses. The label explicitly recommends that the dose be reduced if these symptoms emerge and that the drug be discontinued immediately if the symptoms are severe or are worsening.[22]

This black box warning is the central element in any risk-benefit assessment for perampanel. The potential for such severe behavioral changes, including homicidal ideation, distinguishes it from many other AEDs and necessitates a proactive and vigilant approach to patient management. The fact that these reactions are linked to the drug's fundamental mechanism of modulating the brain's primary excitatory system suggests they are on-target pharmacodynamic effects rather than rare, idiosyncratic reactions. This understanding reinforces that all patients are potentially susceptible, making comprehensive pre-treatment counseling and ongoing monitoring for patients and their caregivers an absolute clinical necessity.

6.2 Common Adverse Events

The most common adverse events associated with perampanel are predominantly CNS-related and exhibit a clear dose-dependent incidence, becoming more frequent and severe as the dose increases.[24]

Table 5: Incidence of Common Treatment-Emergent Adverse Events (TEAEs) in Pooled POS Trials

Adverse Event	Placebo (%)	Perampanel 4 mg (%)	Perampanel 8 mg (%)	Perampanel 12 mg (%)
Dizziness	10	25	35	47
Somnolence	7	12	16	18
Headache	10	12	11	13
Fatigue	5	8	12	15
Irritability	3	6	9	12
Falls	3	4	5	10
Nausea	6	8	8	8
Ataxia	2	3	5	8
Vertigo	1	3	5	5
Weight Gain	3	3	4	4
Data compiled from sources.10

The adverse events most frequently leading to discontinuation of the drug in clinical trials were dizziness, somnolence, vertigo, aggression, anger, and ataxia.[3]

6.3 Other Serious and Clinically Significant Adverse Events

Beyond the boxed warning, several other serious risks require clinical attention:

• Suicidal Ideation and Behavior: In line with the class warning for all AEDs, perampanel is associated with an increased risk of suicidal thoughts and behavior. Patients, families, and caregivers should be instructed to monitor for the emergence or worsening of depression, anxiety, agitation, and any unusual changes in mood or behavior.[3]
• Neurological Effects and Falls: The high incidence of dose-related dizziness, vertigo, ataxia, and gait disturbances leads to a significantly increased risk of falls and subsequent injuries. This risk is particularly pronounced in elderly patients.[3] Patients must be counseled to avoid driving, operating heavy machinery, or engaging in other potentially hazardous activities until they are familiar with how the medication affects their coordination and alertness.[23]
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): This is a rare but potentially fatal multi-organ hypersensitivity reaction that has been reported in postmarketing surveillance. Clinicians and patients should be aware of the signs, which include fever, skin rash, lymphadenopathy, and evidence of internal organ involvement (e.g., hepatitis, nephritis). Prompt recognition and immediate discontinuation of the drug are critical.[24]
• Withdrawal Seizures: As with other AEDs, abrupt discontinuation of perampanel can precipitate an increase in seizure frequency or status epilepticus. A gradual dose reduction is recommended whenever the medication is to be stopped.[28]

6.4 Contraindications and Precautions

The FDA-approved labeling for perampanel does not list any absolute contraindications, apart from a history of known hypersensitivity to the drug or its components.[10]

However, its use is not recommended in several specific patient populations due to a lack of data and potential for increased risk:

• Patients with severe hepatic impairment.[3]
• Patients with severe renal impairment (creatinine clearance <30 mL/min).[3]
• Patients receiving hemodialysis.[3]

Caution is advised when using perampanel in patients with mild to moderate hepatic or renal impairment, and in elderly patients, often requiring slower dose titration and more intensive monitoring.[17]

Part VII: Dosing, Administration, and Patient Management

7.1 Recommended Dosing Regimens

The proper dosing of perampanel is crucial for balancing efficacy and tolerability. It should always be administered orally once daily at bedtime. This timing helps to minimize the impact of its most common CNS side effects, such as dizziness and somnolence, during waking hours.[10] Titration must be done gradually according to individual patient response.

Table 6: Dosing Recommendations in Special Populations and with CYP3A4 Inducers

Patient Group	Starting Dose	Titration Interval	Maximum Recommended Dose
Standard Adult (POS & PGTC)	2 mg once daily	Increase by 2 mg no more than weekly	12 mg once daily
With CYP3A4 Inducers*	4 mg once daily	Increase by 2 mg no more than weekly	12 mg once daily
Mild Hepatic Impairment	2 mg once daily	Increase by 2 mg no more than every 2 weeks	6 mg once daily
Moderate Hepatic Impairment	2 mg once daily	Increase by 2 mg no more than every 2 weeks	4 mg once daily
Elderly	2 mg once daily	Increase by 2 mg no more than every 2 weeks	12 mg once daily (use with caution)
e.g., Carbamazepine, Phenytoin, Oxcarbazepine. Data compiled from sources.10

For partial-onset seizures, the recommended maintenance dose range is 8 mg to 12 mg daily, although some patients may achieve adequate response at 4 mg daily. For primary generalized tonic-clonic seizures, the recommended maintenance dose is 8 mg daily, with a possible increase to 12 mg if needed and tolerated.[10] It is important to recognize that while a 12 mg dose may offer a modest increase in efficacy over an 8 mg dose, it is associated with a substantially higher incidence of adverse reactions.[10]

7.2 Dosage Adjustments for Drug Interactions and Special Populations

Careful dose adjustments are required for specific patient populations and in the presence of interacting medications to ensure safety and efficacy.

• With Concomitant CYP3A4 Inducers: When perampanel is used with potent CYP3A4 inducers such as carbamazepine, phenytoin, or oxcarbazepine, its clearance is significantly increased. To compensate for the resulting lower plasma levels, the starting dose must be doubled to 4 mg once daily.[10]
• Hepatic Impairment: Patients with mild or moderate hepatic impairment have reduced clearance of perampanel. Therefore, a slower titration schedule (no more frequently than every two weeks) and lower maximum daily doses are required: 6 mg for mild impairment and 4 mg for moderate impairment.[10]
• Renal Impairment: Perampanel is not recommended for patients with severe renal impairment or those on hemodialysis. For moderate renal impairment, slower dose titration may be considered.[10]
• Elderly Patients: Due to increased sensitivity to CNS effects and a higher risk of falls, a slower titration schedule of at least two weeks between dose increments is recommended for elderly patients.[10]

7.3 Administration Instructions

Patients should be given clear instructions on how to take their specific formulation of perampanel.

• Tablets: The tablets should be swallowed whole and must not be chewed, crushed, or split, as this can alter the drug's release profile.[11]
• Oral Suspension: The bottle must be shaken well before every administration. The dose must be measured accurately using the provided graduated oral syringe and bottle adapter. Patients should be counseled that a household teaspoon is not an adequate measuring device. The oral suspension should be discarded 90 days after the bottle is first opened.[10]

Part VIII: Significant Drug and Disease Interactions

8.1 Pharmacokinetic Interactions

Perampanel's metabolism via CYP3A4 makes it highly susceptible to pharmacokinetic interactions.

Table 7: Clinically Significant Drug Interactions with Perampanel

Interacting Drug/Class	Effect on Perampanel	Effect of Perampanel	Mechanism	Clinical Recommendation
CYP3A4 Inducers (Carbamazepine, Phenytoin, Oxcarbazepine, Rifampin, St. John's Wort)	↓ Plasma levels by 50-67%	None	Induction of CYP3A4 metabolism	Start perampanel at 4 mg/day. Monitor for reduced efficacy. Dose adjustment may be needed if inducer is added or removed.3
Strong CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin)	↑ Plasma levels	None	Inhibition of CYP3A4 metabolism	Use with caution. Monitor for increased adverse events. Dose reduction of perampanel may be necessary.27
Levonorgestrel Contraceptives	None	↓ Levonorgestrel levels by ~40%	Induction of contraceptive metabolism	Counsel patient that efficacy of hormonal contraceptive may be reduced. Recommend use of a reliable non-hormonal backup method of contraception.3

8.2 Pharmacodynamic Interactions

Pharmacodynamic interactions involve additive or synergistic effects on the central nervous system.

• Alcohol: The interaction between perampanel and alcohol is particularly dangerous and goes beyond simple additive sedation. Co-administration has been shown to significantly worsen mood and markedly increase feelings of anger, hostility, and confusion, while also impairing alertness.[3] This interaction directly potentiates the most severe behavioral risks outlined in the drug's black box warning. Therefore, the recommendation for patients to avoid alcohol while taking perampanel is not merely general advice but a critical risk-mitigation strategy to prevent potentially dangerous behavioral outcomes.
• Other CNS Depressants: Perampanel will have additive CNS depressant effects when taken with other medications that cause drowsiness, such as benzodiazepines, opioids, sedative-hypnotics, and some antihistamines. This can lead to increased dizziness, somnolence, and cognitive and motor impairment.[16]

8.3 Disease-State Interactions

The presence of certain pre-existing medical conditions can increase the risks associated with perampanel therapy.

• Psychiatric and Behavioral Disorders: Perampanel should be used with extreme caution, if at all, in patients with a history of depression, mood disorders, psychosis, or aggressive or hostile behavior.[28]
• Suicidal Tendency: All patients, particularly those with a history of depression or suicidal ideation, must be monitored closely for any worsening of mood or emergence of suicidal thoughts.[29]
• Metabolic Conditions: Perampanel has been associated with weight gain and elevated triglyceride levels. Caution and regular monitoring are advised for patients with obesity, dyslipidemia, or other metabolic risk factors.[29]

Part IX: Conclusion and Clinical Perspective

9.1 Summary of Perampanel's Profile

Perampanel stands as a significant innovation in the field of epileptology, offering a first-in-class mechanism of action by selectively targeting postsynaptic AMPA receptors. This novel approach provides a valuable therapeutic option for patients with epilepsy, particularly those with refractory partial-onset and primary generalized tonic-clonic seizures where other treatments have failed. Its clinical efficacy is supported by a robust program of large-scale clinical trials. The drug's pharmacokinetic profile, defined by a long half-life and primary metabolism via CYP3A4, allows for convenient once-daily dosing but simultaneously demands meticulous attention to dose titration and the management of numerous drug-drug interactions.

9.2 Risk-Benefit Analysis: The Double-Edged Sword

The clinical utility of perampanel can be viewed as a double-edged sword. On one side, it offers clear, evidence-based benefits for reducing seizure burden in patients with difficult-to-control epilepsy. On the other, its use is accompanied by a significant and serious safety liability. The primary clinical challenge in prescribing perampanel is the management of its dose-dependent CNS adverse events, which are headlined by the black box warning for severe, and potentially life-threatening, psychiatric and behavioral reactions. The decision to initiate therapy with perampanel must therefore be a highly individualized one, emerging from a thorough and transparent discussion between the clinician, the patient, and their caregivers that explicitly weighs the potential for seizure control against these profound risks.

9.3 Recommendations for Clinical Practice

To optimize the safe and effective use of perampanel, the following clinical practices are recommended:

• Patient Selection: The ideal candidate for perampanel is often a patient with treatment-resistant epilepsy who has not achieved adequate seizure control with other AEDs. A rigorous screening for any personal or family history of psychiatric conditions, mood instability, or aggressive behavior is an essential prerequisite to prescribing.
• Titration and Dosing Strategy: A conservative "start low, go slow" titration schedule is paramount. This approach not only improves overall tolerability but also provides a critical window to detect the early emergence of adverse behavioral or psychiatric symptoms before they become severe. The clinical goal should always be to identify and use the lowest effective dose that provides meaningful seizure control while minimizing side effects.
• Proactive Monitoring and Education: The use of perampanel necessitates a commitment to proactive and continuous monitoring. This is not a "prescribe and forget" medication. Patients and their families must be thoroughly educated on the specific warning signs detailed in the black box warning—particularly increased irritability, anger, aggression, or any unusual changes in personality—and must be empowered to report these symptoms immediately.
• Holistic Management Approach: Effective use of perampanel requires a holistic view of the patient. Clinicians must carefully review all concomitant medications for potential interactions, especially CYP3A4 inducers and oral contraceptives. Furthermore, lifestyle factors, most notably alcohol consumption, must be addressed directly and emphatically as a key risk-mitigation strategy. By integrating these principles, clinicians can better navigate the complexities of perampanel therapy to maximize its benefits while diligently managing its inherent risks.

Works cited

1. EISAI ANNOUNCES LAUNCH OF ANTIEPILEPTIC DRUG FYCOMPA™ IN U.S., accessed August 3, 2025, https://www.eisai.com/news/news201401.html
2. EUROPEAN COMMISSION APPROVES EISAI'S AMPA RECEPTOR ANTAGONIST FYCOMPA® (PERAMPANEL) | News Release：2012, accessed August 3, 2025, https://www.eisai.com/news/news201249.html
3. Perampanel - Wikipedia, accessed August 3, 2025, https://en.wikipedia.org/wiki/Perampanel
4. Perampanel - PMC - PubMed Central, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3839447/
5. Perampanel | C23H15N3O | CID 9924495 - PubChem, accessed August 3, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Perampanel
6. Summary Review - FDA, accessed August 3, 2025, https://www.fda.gov/media/124207/download
7. Perampanel | CAS 380917-97-5 | Cayman Chemical | Biomol.com, accessed August 3, 2025, https://www.biomol.com/products/chemicals/reference-standards/perampanel-cay23003-5
8. www.biomol.com, accessed August 3, 2025, https://www.biomol.com/products/chemicals/reference-standards/perampanel-cay23003-5#:~:text=Formula%20Weight%3A%20349.4.,soluble%2C%20DMSO%3A%20slightly%20soluble.
9. Fycompa (perampanel) FDA Approval History - Drugs.com, accessed August 3, 2025, https://www.drugs.com/history/fycompa.html
10. FYCOMPA (perampanel) Label - accessdata.fda.gov, accessed August 3, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf
11. Fycompa | European Medicines Agency (EMA), accessed August 3, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa
12. Drug Approval Package: Brand Name (Generic Name) NDA # - accessdata.fda.gov, accessed August 3, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000TOC.cfm
13. Perampanel: Novel Mechanism for the Management of Epilepsy - Practical Neurology, accessed August 3, 2025, https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/perampanel-novel-mechanism-for-the-management-of-epilepsy/30645/
14. What is the mechanism of Perampanel? - Patsnap Synapse, accessed August 3, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-perampanel
15. Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy - PMC, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5083075/
16. Perampanel: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 3, 2025, https://go.drugbank.com/drugs/DB08883
17. Perampanel (as hemisesquihydrate) - Therapeutic Goods Administration (TGA), accessed August 3, 2025, https://www.tga.gov.au/sites/default/files/auspar-perampanel-141014-pi.docx
18. Perampanel - PMC, accessed August 3, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839447/
19. Perampanel Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 3, 2025, https://www.drugs.com/dosage/perampanel.html
20. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305 - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/22905857/
21. On Seizures and Knives: Perampanel-Induced Psychosis: A Case Report and Literature Review - PMC, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11227927/
22. Fycompa (Perampanel Tablets, for Oral Use): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 3, 2025, https://www.rxlist.com/fycompa-drug.htm
23. Side Effects - FYCOMPA® (perampanel) CIII, accessed August 3, 2025, https://www.fycompa.com/side-effects/
24. Fycompa (perampanel) dosing, indications, interactions, adverse effects, and more, accessed August 3, 2025, https://reference.medscape.com/drug/fycompa-perampanel-999784
25. Adverse effects and safety profile of perampanel: a review of pooled data - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/24400692/
26. Fycompa Generic Name: perampanel Manufacturer: Eisai Inc. Drug Class: AMPA Glutamate Receptor Antagonist - WVU School of Pharmacy, accessed August 3, 2025, https://pharmacy.hsc.wvu.edu/media/1152/fycompa-perampanel.pdf
27. Perampanel - Epilepsy Foundation, accessed August 3, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/perampanel
28. Perampanel (oral route) - Side effects & dosage - Mayo Clinic, accessed August 3, 2025, https://www.mayoclinic.org/drugs-supplements/perampanel-oral-route/description/drg-20075877
29. Perampanel Interactions Checker - Drugs.com, accessed August 3, 2025, https://www.drugs.com/drug-interactions/perampanel.html
30. Fycompa and Alcohol/Food Interactions - Drugs.com, accessed August 3, 2025, https://www.drugs.com/food-interactions/perampanel,fycompa.html